Balchem (BCPC) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 earnings from operations and adjusted EBITDA, with strong growth in Human Nutrition & Health and Specialty Products, partially offset by declines in Animal Nutrition & Health.

• Net sales for Q2 2024 increased 1.2% year-over-year to $234.1 million, with net earnings up 6.5% to $32.1 million.

• Gross margin expanded by 210 basis points to 35.5%, and adjusted EBITDA reached a record $62.3 million, up 5.0% year-over-year.

• Maintains leading positions in attractive markets, driven by innovation and a proven track record.

• Launched Optifolin+, a patented, choline-enriched, bioactive folate ingredient targeting the $1.5 billion folic acid market.

Financial highlights

• Q2 2024 net sales: $234.1 million (+1.2% YoY); gross margin: $83.0 million (35.5% of sales); adjusted EBITDA: $62.3 million (+5.0% YoY); adjusted EPS: $1.09.

• Net income: $32.1 million (+6.5% YoY); GAAP EPS: $0.98 (+$0.05 YoY); adjusted net earnings: $35.6 million (+3.3% YoY).

• Cash flow from operations: $45.0 million; free cash flow: $38.4 million; cash balance: $63.7 million.

• Net debt reduced by $35.0 million to $202.8 million; leverage ratio at 0.9x.

• YTD 2024 sales: $473.7 million (+2.1% YoY); adjusted EBITDA: $123.1 million (+6.5% YoY); adjusted net earnings: $69.2 million (+6.4% YoY).

Outlook and guidance

• Expect modest improvement in Animal Nutrition & Health in H2 2024 due to better dairy economics and new product launch.

• Margins anticipated to moderate but stabilize at or above historic rates as raw material deflation is passed to customers.

• Effective tax rate expected to be around 22% for the year.

• Management remains confident in long-term growth, citing strong segment performance and ongoing strategic initiatives.